Generic pharmaceutical manufacturer Natco has secured a compulsory licence to produce cancer drug Nexavar for the Indian market. Ranjna Mehta-Dutt and Shukadev Khuraijam report.
“The beginning is easy; what happens next is much harder”—Anonymous
Against the backdrop of an illusory Indian spring, the Indian patent office bequeathed India’s first compulsory licence to a local generic drug manufacturer: Natco Pharma. In doing so, it placed into practical circulation an untested provision—one it, apparently, considered perfect on paper. Germany’s Bayer, which had been granted the patent in question for its liver/kidney cancer drug Nexavar, has so far kept its future intention on the matter under wraps.
The decision was issued by PH Kurian on his last day in office as the controller general of patents, designs and trademarks. Having essayed many ground-breaking transformations at the patent office during his tenure, he can be said to have ‘gone out with a bang’ after seemingly opening the flood gates with this unprecedented ruling.
The rest of this article is locked for subscribers only. Please login to continue reading.
If you don't have a login, you will need to purchase a subscription to gain access to this article, including all our online content. Please use this link and follow the steps.
For multi-user price options, or to check if your company has an existing subscription to us that we can add you to for FREE, please email Atif Choudhury at firstname.lastname@example.org
compulsory licensing, Natco, pharmaceuticals